Business
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp.  (TSX:  LABS ) (OTC...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results\nTORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (\"MediPharm\", \"MediPharm Labs\" or the \"Company\") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its full year and fourth quarter financial results for the three and twelve months ended December 31st, 2025, before markets open on Monday, March 30th, 2026. MediPharm Labs executive management team will also host a conference call and webcast on Monday March 30th, 2026, at 10:00 a.m. (Eastern time) to discuss the Company’s financial results. Conference Call Dial in Details:North America Toll-Free: (888) 330-2454International Toll: +1 (240) 789-2714Conference ID: 4921762Participants are asked to dial in approximately 15 minutes before the start of the call. Webcast:A webcast will be available by visiting the following link here. For those who are unable to participate on the live conference call or webcast, a replay will be available at https://www.medipharmlabs.com/investors approximately one day after completion of the call. About MediPharm Labs  Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the U...